文献速递白血病

急性髓系白血病诊断与通路的基因组学

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
PubMed 文献 · J Clin Oncol · 2017-02-13

本文综述了高通量测序技术推动下对急性髓系白血病(AML)分子发病机制的理解,包括体细胞突变的功能分类、克隆架构和时序性轨迹,并讨论了遗传数据在疾病分类、风险分层和治疗选择中的应用。

要点

  • 表观遗传修饰基因(如DNMT3A、ASXL1、TET2、IDH1、IDH2)突变常早期获得并存在于 founding clone 中。
  • NPM1或信号分子(如FLT3、RAS)突变通常为白血病发生后期的继发事件。
  • 遗传数据已用于疾病分类、风险分层和临床诊疗,WHO分类新增两个 provisional entity,ELN 2017 风险分层纳入三个基因突变。

核心结论

  • 基因组学研究深化了对AML分子发病机制的理解,遗传数据正用于疾病分类、风险分层和临床诊疗,并指导分子靶向治疗的开发与应用。

研究设计与样本

  • 本文为综述,总结利用高通量测序技术进行的基因组学发现研究,讨论髓系肿瘤(包括AML)的分子发病机制、突变轨迹及临床应用。

主要发现

  • AML以多个影响不同功能类别基因的体细胞获得性突变、复杂克隆架构和疾病随时间演变为特征。
  • 表观遗传修饰基因(DNMT3A、ASXL1、TET2、IDH1、IDH2)突变常早期获得并存在于 founding clone,在老年个体中常与克隆性造血扩展相关,增加血液肿瘤风险,且治疗后可能持续并导致克隆扩展和复发。
  • NPM1或信号分子(如FLT3、RAS)突变通常为白血病发生后期的继发事件。
  • 遗传数据正用于疾病分类、风险分层和临床诊疗;WHO分类当前更新纳入AML伴RUNX1突变和AML伴BCR-ABL1两个 provisional entity;2017 ELN推荐将RUNX1、ASXL1和TP53三个基因突变纳入风险分层。
  • 基线遗传学综合评估与微小残留病评估有望进一步改善风险分层和缓解后治疗选择。

关键数值与推荐

  • WHO分类当前更新纳入两个 provisional entity:AML伴RUNX1突变和AML伴BCR-ABL1。
  • 2017 ELN AML推荐将RUNX1、ASXL1和TP53三个基因突变纳入风险分层。

临床怎么用

  • 遗传数据已用于疾病分类、风险分层和临床诊疗。
  • 基线遗传学综合评估与微小残留病评估有望进一步改善风险分层和缓解后治疗选择。
  • 疾病等位基因的识别将指导新型分子靶向治疗的开发与应用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, our understanding of the molecular pathogenesis of myeloid neoplasms, including acute myeloid leukemia (AML), has been greatly advanced by genomics discovery studies that use novel high-throughput sequencing techniques. AML, similar to most other cancers, is characterized by multiple somatically acquired mutations that affect genes of different functional categories, a complex clonal architecture, and disease evolution over time. Patterns of mutations seem to follow specific and temporally ordered trajectories. Mutations in genes encoding epigenetic modifiers, such as DNMT3A, ASXL1, TET2, IDH1, and IDH2, are commonly acquired early and are present in the founding clone. The same genes are frequently found to be mutated in elderly individuals along with clonal expansion of hematopoiesis that confers an increased risk for the development of hematologic cancers. Furthermore, such mutations may persist after therapy, lead to clonal expansion during hematologic remission, and eventually lead to relapsed disease. In contrast, mutations involving NPM1 or signaling molecules (eg, FLT3, RAS) typically are secondary events that occur later during leukemogenesis. Genetic data are now being used to inform disease classification, risk stratification, and clinical care of patients. Two new provisional entities, AML with mutated RUNX1 and AML with BCR- ABL1, have been included in the current update of the WHO classification of myeloid neoplasms and AML, and mutations in three genes- RUNX1, ASXL1, and TP53-have been added in the risk stratification of the 2017 European LeukemiaNet recommendations for AML. Integrated evaluation of baseline genetics and assessment of minimal residual disease are expected to further improve risk stratification and selection of postremission therapy. Finally, the identification of disease alleles will guide the development and use of novel molecularly targeted therapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bullinger L, Döhner K, Döhner H, et al. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol. 2017. PMID: 28297624. doi:10.1200/JCO.2016.71.2208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。